NASDAQ:VINC Vincerx Pharma (VINC) Stock Price, News & Analysis $0.54 -0.03 (-4.85%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.55 +0.01 (+1.84%) As of 03/28/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vincerx Pharma Stock (NASDAQ:VINC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vincerx Pharma alerts:Sign Up Key Stats Today's Range$0.52▼$0.5750-Day Range$0.54▼$3.0552-Week Range$0.49▼$136.80Volume102,963 shsAverage Volume338,262 shsMarket Capitalization$1.21 millionP/E RatioN/ADividend YieldN/APrice Target$40.00Consensus RatingBuy Company OverviewVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Read More… Remove Ads Vincerx Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreVINC MarketRank™: Vincerx Pharma scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVincerx Pharma has received no research coverage in the past 90 days.Read more about Vincerx Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vincerx Pharma are expected to grow in the coming year, from ($10.00) to ($6.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vincerx Pharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vincerx Pharma is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVincerx Pharma has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vincerx Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.58% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 64.15%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVincerx Pharma does not currently pay a dividend.Dividend GrowthVincerx Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.58% of the float of Vincerx Pharma has been sold short.Short Interest Ratio / Days to CoverVincerx Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vincerx Pharma has recently decreased by 64.15%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.28 News SentimentVincerx Pharma has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Vincerx Pharma this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vincerx Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders15.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vincerx Pharma's insider trading history. Receive VINC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VINC Stock News HeadlinesVincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Down 64.1% in MarchMarch 27 at 2:41 AM | americanbankingnews.comVincerx Pharma announces non-binding LOI for Qumulus AI combinationMarch 18, 2025 | markets.businessinsider.comYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your free gift, and see how Trump's victory could spark major gains for gold.March 29, 2025 | American Alternative (Ad)Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | finanznachrichten.deVincerx Pharma Shares Soar on Proposed Merger with Global Digital HoldingsMarch 18, 2025 | marketwatch.comVincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAIMarch 18, 2025 | globenewswire.comVincerx Pharma announces termination of reverse merger term sheetMarch 1, 2025 | markets.businessinsider.comVincerx Pharma Terminates Reverse Merger Deal With OqoryMarch 1, 2025 | marketwatch.comSee More Headlines VINC Stock Analysis - Frequently Asked Questions How have VINC shares performed this year? Vincerx Pharma's stock was trading at $5.2560 on January 1st, 2025. Since then, VINC shares have decreased by 89.7% and is now trading at $0.5391. View the best growth stocks for 2025 here. How were Vincerx Pharma's earnings last quarter? Vincerx Pharma, Inc. (NASDAQ:VINC) issued its earnings results on Thursday, August, 8th. The company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($3.40) by $2.40. When did Vincerx Pharma's stock split? Vincerx Pharma shares reverse split on the morning of Tuesday, January 28th 2025. The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Vincerx Pharma's major shareholders? Vincerx Pharma's top institutional investors include Geode Capital Management LLC (10.78%). Insiders that own company stock include Ahmed Md Hamdy, Raquel E Izumi, Alexander A Seelenberger and Laura I Bushnell. View institutional ownership trends. How do I buy shares of Vincerx Pharma? Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vincerx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CymaBay Therapeutics (CBAY). Company Calendar Last Earnings8/08/2024Today3/29/2025Next Earnings (Estimated)4/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VINC CIK1796129 Webvincerapharma.com Phone650-800-6676FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$40.00 Low Stock Price Target$40.00 Potential Upside/Downside+7,319.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($20.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-248.33% Return on Assets-132.73% Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.50 per share Price / Book0.05Miscellaneous Outstanding Shares2,240,000Free Float1,891,000Market Cap$1.21 million OptionableNot Optionable Beta1.43 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:VINC) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vincerx Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vincerx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.